the Delhi High Court seeking to restrain NSE -0.15 % Healthcare India from marketing a fully liquid hexavalent vaccine. The national capital-based firm said a case has been filed in order to stop infringement of its patent for fully liquid whole cell pertussis based fully liquid Hexavalent vaccine EasySix. "The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent vaccine by the Drugs Controller General (India)," Panacea Biotec said in a regulatory filing. On May 11, 2021, when the suit was listed before the Delhi High Court, after elaborate submissions from both parties, Sanofi undertook that it could not manufacture or market any product which infringes the amended claims of Panacea patent, it ad